US 11744816
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
granted A61KA61K31/194A61K31/20
Quick answer
US patent 11744816 (Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease) held by Esperion Therapeutics, Inc. expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Esperion Therapeutics, Inc.
- Grant date
- Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/194, A61K31/20, A61K31/397, A61P